A golden age of gene therapy is now in sight

Credit: Rhesus Negative
Credit: Rhesus Negative

To date, just two in vivo gene therapies have been approved in the United States. Both are for what [Duke professor Charles] Gersbach considers the most basic, first-generation gene therapy: take a gene, put it into a vector, and use it to supplement or replace a missing gene product.

In the future, gene therapy will be done earlier. It will, in many cases, be prompted by good screening before any signs or symptoms occur. Treatment decisions could even be informed by tests of egg and sperm. “Then patients would benefit for their entire lifetimes,” [Avrobio’s Chris] Mason prognosticates.

In other cases, there will eventually be machines at the point of care to extract, transduce, and return cells, all in one continuous process. Such a process would be most easily carried out with blood cells. “You are going to have to have some very good algorithms in there that really allow you to know with high confidence that you have cells you want,” Mason details. 


Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

If advances in editing continue, you can anticipate that “in 40 years, the technology may be available to change any base pair of anyone’s genome, in any tissue, in any cell type,” Gersbach says. 

Read the original post

Related article:  ‘One shot’ treatment for hemophilia B uses CRISPR and stem cells
Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend